20 August 2020
Geneva, Switzerland and Radnor, PA August 20, 2020 – RELIEF THERAPEUTICS Holdings SA (SIX:RLF) and NeuroRx, Inc. announce that clinical findings in the first 21 patients treated with RLF-100 (aviptadil) under FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization have been submitted by investigators at the Houston Methodist Hospital as a preprint to the SSRN server maintained by Elsevier. The manuscript has been submitted for peer review to a leading scientific journal.
The Expanded Access Protocol (previously announced by Relief and NeuroRx) is designed to treat patients whose co-morbidities exclude them from enrollment in the ongoing phase 2/3 placebo-controlled trial of RLF-100. Further details can be found on www.clinicaltrials.gov NCT04453839.
Relief notes that an earlier draft of this manuscript was circulated in financial forums by unauthorized persons. Only the manuscript on the SSRN server available under the above link should be considered to represent the official findings of the study. The findings of Dr. Youssef and his team demonstrate that some critically ill patients with COVID-19 experienced substantial clinical improvement when treated with RLF-100. We await the results of the ongoing placebo-controlled trial in order to assess the magnitude of clinical effect.
This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA, NeuroRx, Inc. and their businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
 Youssef JG, Al-Saadi M, Zahiruddin F, Beshay S, Bitar M, Javitt JC, Rapid Recovery from COVID-19 Respiratory Failure with comorbidity in 21 patients treated with Vasoactive Intestinal Peptide (August 20, 2020). Available at http://dx.doi.org/10.2139/ssrn.3665228
2 Please note that the study is still ongoing and the information has not been authored and could not be verified by Relief. Relief disclaims any liability for the information contained therein.